<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801397</url>
  </required_header>
  <id_info>
    <org_study_id>Psy-Rheu_2011/1</org_study_id>
    <nct_id>NCT01801397</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Study Title:&#xD;
&#xD;
      A pilot study to evaluate the effect of Forsteo® (Teriparatide, 1-34 rh-PTH) in Anorexia&#xD;
      Nervosa patients with low mineral density and increased bone fragility (FAN-Trial)&#xD;
&#xD;
      Short Title/Study ID:&#xD;
&#xD;
      FAN-Trial / Psy-Rheu_2011/1&#xD;
&#xD;
      Indication:&#xD;
&#xD;
      Low bone mineral density (Z-Score &lt; -1.5 or T-Score &lt; -1.5 if available) and fragility&#xD;
      fractures or very low bone mineral density (Z-Score &lt; -2.5 or T-Score &lt;-2.5 if available)&#xD;
      without fragility fractures in Anorexia Nervosa patients&#xD;
&#xD;
      Trial Design:&#xD;
&#xD;
      Open-label, single-centre pilot study with study drug treatment duration of 24 months.&#xD;
&#xD;
      Study Center:&#xD;
&#xD;
      Single-centre (University Hospital of Zürich)&#xD;
&#xD;
      Investigator(s)/Authors:&#xD;
&#xD;
      PD Dr. med Gabriella F. Milos (Principle Investigator and author), Dept of Psychiatry, Centre&#xD;
      for Eating Disorders, University Hospital Zürich, CH-8091 Zürich Dr. med. Diana P. Frey&#xD;
      (Co-Investigator and author), Dept. of Rheumatology, University Hospital Zürich, CH-8091&#xD;
      Zürich PD Dr. med. Daniel Uebelhart (author), SUVA Fribourg, CH-1701 Fribourg&#xD;
&#xD;
      Objective(s)/Outcome(s):&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      •To assess the efficacy of Teriparatide (Forsteo®) in increasing the bone mineral density in&#xD;
      the lumbar spine, total hip and femoral neck in patients with anorexia nervosa and low bone&#xD;
      density at months 12 and 24.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  To assess the changes in blood biomarkers&#xD;
&#xD;
        -  To assess changes in whole body composition&#xD;
&#xD;
        -  To assess the incidence of new fragility fractures&#xD;
&#xD;
        -  To assess changes in bone structure&#xD;
&#xD;
        -  To assess the changes in EDE-Q&#xD;
&#xD;
        -  Longterm safety and tolerability of Teriparatide (Forsteo®) in patients with AN&#xD;
&#xD;
      Assessments for primary endpoint:&#xD;
&#xD;
      •BMD at lumbar spine, total hip and femoral neck, measured by DXA&#xD;
&#xD;
      Assessments for secondary endpoints:&#xD;
&#xD;
        -  bone resorption and bone formation markers measured in urine and serum&#xD;
&#xD;
        -  whole body composition measured by DXA&#xD;
&#xD;
        -  New clinical peripheral and vertebral fractures&#xD;
&#xD;
        -  HRqCT of tibia and forearm&#xD;
&#xD;
        -  EDE-Q Score at months 12 and 24&#xD;
&#xD;
      Safety measurements:&#xD;
&#xD;
        -  Safety lab (blood and urine)&#xD;
&#xD;
        -  Clinical adverse event monitoring at all visits Number of Subjects: 10&#xD;
&#xD;
      Diagnosis and Main Inclusion Criteria:&#xD;
&#xD;
        -  Women, aged &gt; 18 to &lt; 35 years&#xD;
&#xD;
        -  Having severe anorexia nervosa (AN) (DSM-IV-R) for &gt; 12 months before screening&#xD;
&#xD;
        -  Presenting with very low bone mineral density (defined as Z-Score &lt; -2.5 or T-Score &lt;&#xD;
           -2.5 if available) of at least one of the assessed localizations (lumbar spine L1 - L4,&#xD;
           total hip, femoral neck) without any previous fragility fracture&#xD;
&#xD;
        -  or low bone mineral density (defined as Z-Score &lt; -1.5 or T-Score &lt; -1.5 if available)&#xD;
           of at least one of the assessed localizations (lumbar spine L1 - L4, total hip, femoral&#xD;
           neck) and at least one previous fragility fracture&#xD;
&#xD;
        -  In- and out-patients of the Centre for Eating Disorders at the Clinic for Psychiatry and&#xD;
           Psychotherapy of the University Hospital of Zurich.&#xD;
&#xD;
      Main Exclusion Criteria:&#xD;
&#xD;
        -  Metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism,&#xD;
           osteomalacia, Paget's disease of bone), pre-existing hypercalcemia, severe renal&#xD;
           impairment (GFR &lt; 30 ml/min), prior external beam or implant radiation therapy to the&#xD;
           skeleton, skeletal malignancies or bone metastases, any unknown elevation of serum&#xD;
           alkaline phosphatase, severe psychiatric diseases other than AN, drug addiction, HIV&#xD;
           positive patients, pregnancy, open epiphyses&#xD;
&#xD;
        -  Incapacity to understand the aims of the study or patients not willing to collaborate.&#xD;
&#xD;
      Study Product, Dose, Route, Regimen:&#xD;
&#xD;
      Teriparatide (Forsteo®), 20µg s.c. daily for 24 months.&#xD;
&#xD;
      Duration of study:&#xD;
&#xD;
      24 months.&#xD;
&#xD;
      Reference therapy, Dose, Route, Regimen:&#xD;
&#xD;
      NA&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of Teriparatide (Forsteo®) in increasing the bone mineral density in the lumbar spine, total hip and femoral neck in patients with anorexia nervosa and low bone density at months 12 and 24.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Low Bone Mass in Anorexia Nervosa Patients</condition>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>one arm study. All patients receive teriparatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>osteoanabolic therapy</intervention_name>
    <arm_group_label>Teriparatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: •Women, aged &gt; 18 to &lt; 35 years&#xD;
&#xD;
          -  Having severe anorexia nervosa (AN) (DSM-IV-R) for &gt; 12 months before screening&#xD;
&#xD;
          -  Presenting with very low bone mineral density (defined as Z-Score &lt; -2.5 or T-Score &lt;&#xD;
             -2.5 if available) of at least one of the assessed localizations (lumbar spine L1 -&#xD;
             L4, total hip, femoral neck) without any previous fragility fracture&#xD;
&#xD;
          -  or low bone mineral density (defined as Z-Score &lt; -1.5 or T-Score &lt; -1.5 if available)&#xD;
             of at least one of the assessed localizations (lumbar spine L1 - L4, total hip,&#xD;
             femoral neck) and at least one previous fragility fracture&#xD;
&#xD;
          -  In- and out-patients of the Centre for Eating Disorders at the Clinic for Psychiatry&#xD;
             and Psychotherapy of the University Hospital of Zurich.&#xD;
&#xD;
        Exclusion criteria: Metabolic bone diseases other than primary osteoporosis (including&#xD;
        hyperparathyroidism, osteomalacia, Paget's disease of bone), pre-existing hypercalcemia,&#xD;
        severe renal impairment (GFR &lt; 30 ml/min), prior external beam or implant radiation therapy&#xD;
        to the skeleton, skeletal malignancies or bone metastases, any unknown elevation of serum&#xD;
        alkaline phosphatase, severe psychiatric diseases other than AN, drug addiction, HIV&#xD;
        positive patients, pregnancy, open epiphyses&#xD;
&#xD;
        •Incapacity to understand the aims of the study or patients not willing to collaborate.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriella Milos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Department of Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frey Diana, MD</last_name>
    <email>diana.frey@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gabriella Milos, MD</last_name>
    <email>gabriella.milos@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Department of Psychiatry</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich, Rheumatology Department</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana P Frey, MD</last_name>
      <email>diana.frey@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Diana P Frey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

